ACST Stock – (NASDAQ: ACST) is actually giving an update on the use
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually providing an update on the use of its “at the market” equity providing plan.
As earlier disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to put into practice an “at-the market” equity offering system under which Acasti may issue as well as promote from time to time the everyday shares of its having an aggregate offering price of up to $75 million in the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions reported on January twenty seven, 2021, Acasti given an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 million. The ATM Shares ended up being marketed at prevailing market prices averaging US$1.0747 a share. No securities were marketed throughout the facilities of the TSXV or, to the knowledge of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333-239538) as made effective on July seven, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with their services. As a result of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and outstanding as of March five, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and will supply the Company with more flexibility in its continuous review process to check out and evaluate strategic alternatives.
Approximately Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically concentrated on the research, commercialization and development of prescription drugs making use of OM3 fatty acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have extensive clinical proof of efficacy as well as safety for lowering triglycerides in individuals with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being created for patients with serious HTG.
Forward Looking Statements – ACST Stock
Statements of that press release that aren’t statements of historical or current fact constitute “forward looking information” to the meaning of Canadian securities laws and “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward-looking claims include known and unknown risks, uncertainties, and other unknown variables that can cause the particular results of Acasti to be materially different from historical success and even as a result of any future outcomes expressed or even implied by such forward looking statements. In addition to statements which explicitly describe these types of risks as well as uncertainties, readers are urged to give some thought to statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other similar expressions to be forward-looking and uncertain. Readers are cautioned not to place undue reliance on these forward looking statements, which speak only as of the day of this press release. Forward-looking assertions in this press release include, but are not restricted to, info or statements concerning Acasti’s strategy, succeeding operations and its review of strategic options.
The forward looking claims contained in this specific press release are expressly qualified in the entirety of theirs by this alerting declaration, the “Special Note Regarding Forward-Looking Statements” area found in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10-Q, which are actually readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and also on the investor area of Acasti’s site at www.acastipharma.com. Many forward-looking statements in this press release are manufactured as of the day of this press release.
ACST Stock – Acasti doesn’t undertake to redesign some such forward looking statements whether as a result of info that is brand new , future events or even otherwise, except as required by law. The forward looking assertions contained herein are also subject typically to assumptions and risks as well as uncertainties that are described from time to time in Acasti’s public securities filings with the Securities and exchange Commission and The Canadian securities commissions, like Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is providing an update on the use